Penn Medicine Cancer Team's "Serial Killer" T Cell Leukemia Treatment Named Among Nation's Top Clinical Research Achievements

April 19, 2012

Penn Medicine News

WASHINGTON — Carl June, MD, director of Translational Research for the Abramson Cancer Center and a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at University of Pennsylvania, has been named among the top three winners of the inaugural Clinical Research Forum Top 10 Clinical Research Achievement Awards for his work treating chronic lymphocytic leukemia using genetically engineered versions of patients' own T cells, which multiply in the body as "serial killer" cells aimed at cancerous tumors. His team's findings, which have drawn a new map for the treatment of ovarian and pancreatic cancers and mesothelioma, were published in the New England Journal of Medicine and Science Translational Medicine in August 2011.

The Clinical Research Forum, a nonprofit organization dedicated to providing national leadership in clinical research and promoting understanding of its impact on health and health care delivery, hails the winning studies as being "remarkable for their bold approaches, innovation and potential for alleviating human suffering." The projects are compelling examples of the scientific innovation that results from the nation's investment in clinical research that can benefit human health and welfare, underscoring the importance of this support even in lean economic times... Read More